Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China

Zhike Liu1*, MD; Liang Zhang2*, BSc; Yu Yang3, MD; Ruogu Meng3, MD; Ting Fang2, MM; Ying Dong2, MM; Ning Li2, MM; Guozhang Xu2, MM; Siyan Zhan1, MD

1Department of Epidemiology and Biostatistics, Peking University Health Science Center, Beijing, China
2Ningbo Municipal Center for Disease Control and Prevention, Ningbo, China
3National Institute of Health Data Science, Peking University, Beijing, China
*these authors contributed equally

Abstract

Background: Comprehensive safety data for vaccines from post-licensure surveillance, especially active surveillance, could guide administrations and individuals to make reasonable decisions on vaccination. Therefore, we designed a pilot study to assess the capability of a regional health care information platform to actively monitor the safety of a newly licensed vaccine.

Objective: This study aimed to conduct active surveillance of human papillomavirus (HPV) vaccine safety based on this information platform.

Methods: In 2017, one of China’s most mature information platforms with superior data linkage was selected. A structured questionnaire and open-ended interview guidelines were developed to investigate the feasibility of active surveillance following HPV vaccination using the regional health care information platform in Ningbo. The questionnaire was sent to participants via email, and a face-to-face interview was conducted to confirm details or resolve discrepancies.

Results: Five databases that could be considered essential to active surveillance of vaccine safety were integrated into the platform starting in 2015. Except for residents' health records, which had a coverage rate of 87%, the data sources covered more than 95% of the records that were documented in Ningbo. All the data could be inherently linked using the national identity card. There were 19,328 women who received the HPV vaccine, and 37,988 doses were administered in 2017 and 2018. Women aged 30-40 years accounted for the largest proportion. Quadrivalent vaccination accounted for 73.1% of total vaccination, a much higher proportion than that of bivalent vaccination. Of the first doses, 60 (60/19,328, 0.31%) occurred outside Ningbo. There were no missing data for vaccination-relevant variables, such as identity card, vaccine name, vaccination doses, vaccination date, and manufacturer. ICD-10 coding could be used to identify 9,180 cases using a predefined list of the outcomes of interest, and 1.88% of these cases were missing the identity card. During the 90 days following HPV vaccination, 4 incident cases were found through the linked vaccination history and electronic medical records. The combined incident rate of rheumatoid arthritis, optic neuritis, and Henoch-Schonlein purpura was 8.84/100,000 doses of bivalent HPV, and the incidence rate of rheumatoid arthritis was 3.75/100,000 doses of quadrivalent HPV.

Conclusions: This study presents an available approach to initiate an active surveillance system for adverse events following HPV vaccination, based on a regional health care information platform in China. An extended observation period or the inclusion...
of additional functional sites is warranted to conduct future hypothesis-generating and hypothesis-confirming studies for vaccine safety concerns.

**KEYWORDS**
safety; HPV; human papillomavirus; vaccine; active surveillance

**Introduction**

Vaccines, unlike drugs, are generally administered to healthy populations, so the target sample is much larger, especially for birth cohorts, children, or pregnant women. Concerns around vaccine safety, especially for rare adverse events, are increasing with the success of vaccines for the control of vaccine-preventable diseases [1,2]. These concerns can cause a lack of confidence in vaccines and further vaccine hesitancy, defined as a delay in the acceptance or refusal of vaccines despite the availability of vaccination services, that impede or undermine the efforts of an immunization program [3,4]. Although pre-licensure trials can assess the relationship between a vaccine and common adverse events, this type of trial does not have sufficient power to determine the general risk of rare diseases. Therefore, comprehensive safety data from post-licensure surveillance should be used to evaluate the benefit-risk ratio of vaccines, allowing evidence-based decisions by individuals and health organizations [5,6].

Surveillance of adverse events following immunization (AEFI), especially active surveillance for AEFI, should be an essential part of an immunization program to guarantee the safety of vaccines and help establish public confidence [7]. Worldwide, there are a variety of approaches for active AEFI surveillance. Of these approaches, two are the most recognized and replicated due to their robustness and continuity [7]: Vaccine Safety Datalink (VSD), consisting of population-based distributed datasets [8,9], and IMPACT, consisting of targeted hospital-based surveillance [10,11]. These systems were primarily created by developed countries, and limited such systems are available in developing countries [12]. Because of its large population, vast area, and different racial and cultural backgrounds, evidence of vaccine safety in China, especially from active surveillance, can contribute to global vaccine safety efforts.

In recent years, the number of electronic health data sources and interest in their applications have rapidly increased with the advances in medical information systems in China [13], and these electronic health databases could provide the potential for drug safety surveillance and pharmacoepidemiology [14]. Among the electronic health data sources, regional health data sources have been successfully used for drug safety evaluations and surveillance of chronic diseases [15,16]. However, very little is known about the capacity of this data source for active surveillance of adverse events following immunization, and increasing importance has been given to feasibility assessments as essential technical evaluations before starting any vaccine epidemiologic study. Here, we aimed to conduct a feasibility assessment for active surveillance of human papillomavirus (HPV) vaccine safety using the regional health data platform in the city of Ningbo, including a description of the database stakeholders and components, evaluation of the completeness of data relevant to HPV vaccine safety, and an examination of the linkage of data between different data sources.

**Methods**

**Study Setting and Data Sources**

Ningbo is a city in the Zhejiang province of China (28°51’ – 30°33’ N, 120°55’ – 122°16’ E). It is located in the south wing of the Yangtze River Delta and consists of 4 counties (Yuyao, Cixi, Ninghai, and Xiangshan) and 6 districts (Yinzhou, Haishu, Jiangbei, Zhenhai, Beilun, and Fenghua), with a total land area of 9365 km². In 2017, the city population was >8 million people, and nearly 6 million are part of the hukou (ie, registration of an individual) of Ningbo. The resident population is relatively stable, with a 4.1% out-migration rate and 11.1% in-migration rate.

The regional health care information platform in Ningbo was initially devised and launched in 2011 by the Health Commission of Ningbo to construct a united and standardized medical information network and facilitate health care services. By 2015, the database covered almost all health-related activities of residents within this area, and more than 87% of the residents were registered in the database with a valid health care identifier. In 2016, the database was approved and awarded a Four Grade Class A, which at the time was the top achievement level by the Standardization and Maturity Measurement of Regional Health Information Interconnection by the National Health Commission of China.

**Questionnaire Design and Field Investigation**

Based on information in previous studies, we developed the questionnaire and open-ended interview guidelines to evaluate the feasibility of active surveillance following HPV vaccination using the regional health care information platform in Ningbo. To finalize the questionnaire and guidelines, four experts from pharmacoepidemiology, vaccine safety, medical informatics, and database administration independently reviewed the documents and provided feedback. Then, a 2-step survey was conducted to collect database information from the data owners, management, and other staff. First, we sent the questionnaire, its instructions, a comprehensive description of the study purpose, and the completion deadline to the database staff via email. After receiving the questionnaire responses, we confirmed any potential discrepancies with Ningbo through telephone communication. Second, we conducted face-to-face interviews, using the open-ended interview guidelines, with relevant staff during field visits.
The questionnaire about the database consisted of 7 parts: (1) basic information in the database; (2) information in electronic medical records (EMR) in the database; (3) vaccination registration and information about maternal and child health care in the database; (4) method and possibility of linking data between different data sources; (5) age distribution of HPV vaccine–protected women in 2017; (6) completeness of core variables relevant to active surveillance of vaccine safety in 2017; and (7) crucial outcome information in EMR in 2017.

The interview guideline was mainly composed of 3 parts: (1) general characteristics of the database; (2) general characteristics of the essential information system for active surveillance, including vaccination registration, EMR, maternal and child health care information, cancer registration, death registration; and (3) other several specific questions.

The study was approved by the Peking University Institutional Review Board (IRB 00001052-18016). Moreover, all the tasks were performed by staff of the data owner, and investigators could not access the raw data throughout the study period.

Results

Stakeholders and Database Components in Ningbo

The Ningbo database was constructed and is owned by the Ningbo Health Commission (NHC), and the Ningbo Centers for Disease Control and Prevention (CDC) can operate and develop this database with permission from the NHC. There are two primary data sources in the database, including the digital CDC platform and digital hospital platform. The CDC controls the former, which mainly focuses on public health and provides a unified information system for the whole city, including integrated primary health care, chronic or infectious disease surveillance, vaccine registration (children and adults), and death registration. Data in the hospital digital platform are collected during regular clinical services provided in hospitals, such as from EMR, and the information system usually differs by hospital, but the NHC has developed harmonized standards to transform and upload these data, which are in a nearly structured format in the Ningbo database. Moreover, the NHC and CDC have endeavored to improve the data quality in the database through official regulations, upgrading of standards, and regular quality checks. The local CDC has also established an institutional review board to review ethical issues and guarantee privacy protection during the process of scientific research.

Characteristics of the Data Sources for Active Surveillance of HPV Vaccine Safety

Table 1 summarizes the characteristics of the five data sources related to active surveillance for HPV vaccine safety in the Ningbo database; data from these sources were updated and uploaded into the database daily. First, residents’ electronic health records were created primarily by general physicians when the residents visited medical and health institutions for services; these records currently cover >87% of the permanent residents in Ningbo. Second, all vaccination records, including free vaccines provided by the Expanded Programme on Immunization or vaccines paid for out-of-pocket, for infants and children aged <6 years are registered in the immunization program system. It was a compulsory requirement from the Ningbo CDC beginning in May 2017 that vaccination records for adults be registered. Third, starting in 2015, the platform integrated new and historical EMR data from all public hospitals and most of the large private hospitals in the city. Fourth, the maternal and child health care information system includes data recorded during health care services provided for prenatal examinations, maternal deliveries, and newborn follow-ups (until the infant was 1 year old), which resulted in an increase in the local pregnancy and maternal registration rate to 97% by 2016. Finally, the death surveillance information system primarily includes identity information and medical certificates of the dead and can trace death records outside of the city of Ningbo but inside Zhejiang province.
Table 1. Characteristics of the data sources related to HPV vaccine safety surveillance.

| Data and population | Year surveillance began | Coverage | Main purpose |
|---------------------|-------------------------|----------|--------------|
| **RHR**a | | | |
| Residents | 2010 | >87% of permanent residents | Basic information, health checks, special population primary care |
| **IP**b | | | |
| Children | 2005 | 100% for 167 vaccination clinics | Basic information, vaccination records, vaccine cold chain |
| Adults | 2017 | | |
| **EMR**c | | | |
| Outpatientsd | 2015 | All 221 public health hospitals and 28 large private hospitals | Diagnoses, prescriptions, medical examinations, lab tests |
| Inpatients | 2015 | | |
| **MCH**e | | | |
| Maternal patients | 2015 | >97% maternal registration rate | Prenatal examinations, birth deliveries, newborn follow-ups |
| Newborns | 2015 | | |
| **DS**f | | | |
| Residents | 2010 | Permanent residents | Identity, death certificates |

aRHR: residents’ health records.  
bIP: immunization program.  
cEMR: electronic medical record.  
dincludes outpatient and emergency visits.  
eMCH: maternal and child health care.  
fDS: death surveillance.

Characteristics of HPV Vaccination in the Immunization Program

From 2017 to 2018, there were two types of HPV vaccines: bivalent and quadrivalent. Both were only available for women in this district. Table 2 describes the characteristics of the population who received the HPV vaccination in Ningbo. During this period, 19,328 women received at least one dose of the HPV vaccine. Women aged 30-40 years represented the largest proportion. Quadrivalent vaccination was administered more often than bivalent vaccination. Moreover, 60 (60/19,328, 0.31%) first doses seemingly occurred outside Ningbo, and these data were not traced back to the database.

The completeness of critical variables relevant to HPV vaccination (e.g., recipient identity card [ID], name, gender, birth date, address, vaccine name, vaccination date, vaccination manufacturer, batch number) was also investigated, and for these variables, there were no missing data. The system did not have information for education, occupation, height, weight, smoking habits, and alcohol consumption.
Table 2. Characteristics of the women who underwent HPV vaccination.

| Variables     | Total (n=19,328), n (%) | First dose (n=19,268), n (%) | Second dose (n=13,404), n (%) | Third dose (n=5316), n (%) |
|---------------|-------------------------|-----------------------------|-------------------------------|----------------------------|
| Age group (years)                  |                         |                             |                               |                            |
| 9-15          | 1541 (7.97)             | 1532 (7.95)                 | 1343 (10.02)                  | 613 (11.53)                |
| 16-20         | 959 (4.96)              | 943 (4.89)                  | 806 (6.01)                    | 491 (9.24)                 |
| 21-25         | 2735 (14.15)            | 2721 (14.12)                | 1961 (14.63)                  | 1064 (20.02)               |
| 26-30         | 3221 (16.66)            | 3215 (16.69)                | 1966 (14.67)                  | 634 (11.93)                |
| 31-35         | 4146 (21.45)            | 4138 (21.48)                | 2554 (19.05)                  | 759 (14.28)                |
| 36-40         | 4117 (21.30)            | 4112 (21.34)                | 2753 (20.54)                  | 902 (16.97)                |
| 41-45         | 2609 (13.50)            | 2607 (13.53)                | 2021 (15.08)                  | 853 (16.05)                |
| Vaccine       |                         |                             |                               |                            |
| Bivalent      | 5194 (26.87)            | 5147 (26.71)                | 4445 (33.16)                  | 1721 (32.37)               |
| Quadrivalent  | 14134 (73.13)           | 14121 (73.29)               | 8959 (66.84)                  | 3595 (67.63)               |

Identification of the Outcome of Interest in EMR

Table 3 shows the ability of the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes to identify the safety outcomes of interest in EMR as well as the incident cases of diseases 90 days after HPV vaccination. All visit records of the cases were retrieved from the EMR using standard query language and the ICD-10 code, and duplicate records were removed. As a result, for data from 2017 and 2018, ICD-10 codes can be used to identify all the outcomes of interest in women aged 9-45 years. Among these diseases, there were 1867 cases of systemic lupus erythematosus, which was the largest proportion of cases. In contrast, there were only 2 cases of acute disseminated encephalomyelitis, which was the smallest proportion of cases. Except for that of Henoch-Schönlein purpura (HSP; 118/1606, 7.35%), the rate of missing IDs for other diseases was near or <5%, and the total rate of missing IDs was 1.88% (173/9180).

Moreover, we monitored the risk of specific adverse events during the 90 days after HPV vaccination. For all the doses, we found 4 incident cases with no history of the disease at least 1 year before HPV vaccination. Two new cases, one each of rheumatoid arthritis (RA) and optic neuritis (ON), were diagnosed within 30 days of bivalent HPV vaccination, and one new case of HSP was diagnosed within 90 days of bivalent HPV vaccination. One new case of RA emerged within 90 days after quadrivalent HPV vaccination.

Hospitals not included in the database could not diagnose nor treat the outcomes of interest. Regarding case validation, structured data from imaging examinations, laboratory tests, histological examinations, and other medical examinations could be found directly in the database, while nonstructured or free-text information, such as the chief complaint, may have needed to be retrieved from the hospital.
| Disease                                | ICD-10<sup>a</sup> | n<sup>b</sup> | ID<sup>c</sup> missing, n (%) | New cases 30 days post-HPV<sup>d</sup> vaccination, n | New cases 90 days post-HPV vaccination, n |
|----------------------------------------|---------------------|--------------|-------------------------------|-------------------------------------------------|---------------------------------|
| Rheumatologic/autoimmune diseases      |                     |              |                               |                                                 |                                 |
| SLE<sup>e</sup>                        | M32                 | 1867         | 39 (2.09)                     | 0                                               | 0                               |
| RA<sup>f</sup>                         | M05, M06            | 2878         | 72 (2.50)                     | 1                                               | 2                               |
| JRA<sup>g</sup>                        | M08.0               | 52           | 3 (5.77)                      | 0                                               | 0                               |
| Inflammatory bowel disease (IBD)       |                     |              |                               |                                                 |                                 |
| Crohn disease                          | K50                 | 135          | 6 (4.44)                      | 0                                               | 0                               |
| Ulcerative colitis                     | K51                 | 787          | 17 (2.16)                     | 0                                               | 0                               |
| Autoimmune endocrine conditions        |                     |              |                               |                                                 |                                 |
| Type 1 diabetes                        | E10                 | 369          | 18 (4.88)                     | 0                                               | 0                               |
| Autoimmune thyroiditis                 | E06.3               | 126          | 2 (1.59)                      | 0                                               | 0                               |
| Graves’ disease                        | E05.0               | 362          | 5 (1.38)                      | 0                                               | 0                               |
| Autoimmune neurologic and ophthalmic conditions |     |              |                               |                                                 |                                 |
| Multiple sclerosis                     | G35                 | 30           | 0 (0)                         | 0                                               | 0                               |
| ADEM<sup>h</sup>                       | G04.0               | 2            | 0 (0)                         | 0                                               | 0                               |
| GBS<sup>i</sup>                        | G61.0               | 11           | 0 (0)                         | 0                                               | 0                               |
| Neuromyelitis optica                   | G36.0               | 35           | 1 (2.86)                      | 0                                               | 0                               |
| ON<sup>j</sup>                         | H46                 | 346          | 16 (4.62)                     | 1                                               | 1                               |
| Others                                 |                     |              |                               |                                                 |                                 |
| ITP<sup>k</sup>                        | D69.3|4            | 279                           | 4 (1.43)                                       | 0                               |
| HSP<sup>l</sup>                        | D69.0               | 1606         | 118 (7.35)                    | 0                                               | 1                               |
| Bell’s palsy                           | G51.0               | 105          | 5 (4.76)                      | 0                                               | 0                               |
| VTE<sup>m</sup>                        | I82.8|9            | 59                            | 3 (5.08)                                       | 0                               |
| Raynaud’s disease                      | I73.0               | 131          | 1 (0.76)                      | 0                                               | 0                               |
| Total                                  | N/A<sup>n</sup>     | N/A<sup>n</sup>| N/A<sup>n</sup>         | 2                                               | 4                               |

<sup>a</sup>ICD-10: 10th revision of the International Statistical Classification of Diseases and Related Health Problems.

<sup>b</sup>duplicate records were removed, and the number of patients was calculated using an encoded identifier consisting of the identity card or name, gender, birth date, and address.

<sup>c</sup>ID: identity card, which is unique for each individual in China.

<sup>d</sup>HPV: human papillomavirus.

<sup>e</sup>SLE: systemic lupus erythematosus.

<sup>f</sup>RA: rheumatoid arthritis.

<sup>g</sup>JRA: juvenile rheumatoid arthritis.

<sup>h</sup>ADEM: acute disseminated encephalomyelitis.

<sup>i</sup>GBS: Guillain-Barre syndrome.

<sup>j</sup>ON: optic neuritis.

<sup>k</sup>ITP: primary immune thrombocytopenia.

<sup>l</sup>HSP: Henoch-Schönlein purpura.

<sup>m</sup>VTE: venous thromboembolism.

<sup>n</sup>N/A: not applicable.
Discussion

Principal Findings

A feasibility assessment is the first step to improve the quality of study protocols and accelerate regulatory approvals and, in turn, the start of an actual study [17]. The regional health care information platform in Ningbo covers the entire city and has integrated the essential data sources for active surveillance of the HPV vaccine, including immunization program registration, EMR, resident health records, and death surveillance; these data can be linked using the unique national ID or encoded identifier. More importantly, this database can sensitively identify the outcome of interest through ICD-10 coding, so we can actively monitor risks following HPV vaccination by linking HPV vaccination records with adverse events from EMR, death, or other data sources. Therefore, this database could be available and feasible in research for active surveillance of adverse events following HPV vaccination.

Comparison With Prior Work

The Chinese CDC established the AEFI Surveillance System, which is a passive national surveillance system covering more than 29 provinces, in 2015 [18]. However, regarding active surveillance, the relevant studies have used traditional methods for timely collection of adverse events, such as by telephone or daily cards, that were designed and performed during the H1N1 pandemic [19]. Plus, we have not found a study that attempted to construct a sustained active surveillance system for AEFI despite the large population and vast geographical area in China [7]. Internationally, some countries have developed sustainable active surveillance systems for adverse events using population-based databases that link vaccine history with outcomes, such as the VSD [9] and Post-Licensure Rapid Immunization Safety Monitoring program [20]. In this study, considering that the crucial data components in the Ningbo database are similar to those in the VSD and Post-Licensure Rapid Immunization Safety Monitoring program, we consider this to be pioneering work in China – to construct a continuous method for actively monitoring AEFI during the post-marketing phase of vaccines. Moreover, we can also link vaccination history with death records in the Ningbo database, which might reduce potential bias from right-censored data.

In this study, of the specific list of outcomes, we identified 4 incident cases within the 90 days following HPV vaccination. The combined incident rate of RA, ON, and HSP was 8.84/100,000 doses of bivalent HPV, and the incident rate of RA was 3.75/100,000 doses of quadrivalent HPV. There was no cluster of these adverse events. Considering the prevalence of RA is 0.46% [21] and the lack of large epidemiology studies of ON [22] and HSP in Chinese women, the rate of adverse events was not high enough for a safety signal. Furthermore, an updated systematic review concluded that the risk of RA, ON, or HSP is not increased with any type of HPV vaccine [23]. However, due to the limited sample size and different backgrounds of Chinese women, a larger sample or longer observational period is required to comprehensively review the safety of HPV vaccines in China.

To monitor the long-term safety of HPV vaccines, a continuous, sustainable surveillance system is necessary. There are several ways of setting controls to promptly identify and alert of vaccine safety signals. First, comparing with historical controls, or background rates, is an approach to identify whether the incidence rate of adverse events following vaccination is higher than the background rate, which is not due to chance [24]. However, it may not be feasible to perform this comparison in the Ningbo database due to the short premarketing period of the HPV vaccine. Four study designs were recently recognized and have become widespread for vaccine safety surveillance, including the self-controlled case series (SCCS), self-controlled risk interval (SCRI), cohort, and case-control study designs [25], and SCRI and SCCS have been proven to be an efficient, rational alternative to the cohort in a simulation study [25,26]. In a real-world study, self-controlled analyses, such as those used in SCRI and SCCS, are used because each case acts as its own control within a short period, thereby inherently adjusting for all time-unvarying potential confounders, such as sex, nationality, and genetic predisposition [27,28]. In our study, given that the database can only capture the visit records of safety outcomes and HPV vaccines that occurred in the city, it is likely that we will misclassify these crucial variables in a subsequent study; for example, some local young women can be vaccinated while attending college outside the city. In addition, these records cannot currently be traced back to the Ningbo database unless the women return to Ningbo and utilize the relevant local services.

Therefore, using the SCRI as the primary design to evaluate the risk after vaccination seems most appropriate, minimizing misclassification bias due to incomplete vaccine exposure. A cohort study as the secondary design may improve statistical power [28]. Also, additional regional databases need to be incorporated to increase the robustness of risk estimation, especially for different subpopulations or districts.

Limitations

Some potential barriers need to be overcome in additional studies. First, because the HPV vaccination rate is so low in Ningbo, the observation period should be lengthened, or additional sites should be incorporated. Second, identification algorithms for safety outcomes should be developed to improve performance, with a positive predictive value >70% [29]. Third, migration may cause potential bias in the representative population or misclassification of exposure and outcomes, so we should consider its influence in future research. Finally, missing links between data should be addressed and balanced with privacy concerns [30].

Conclusions

The study presents an available approach to initiate an active surveillance system for adverse events after HPV vaccination, based on a regional health care information platform in China. Utilizing a longer observation period or including additional functional sites is warranted to conduct future hypothesis-generating and hypothesis-confirming studies to address vaccine safety concerns.
Acknowledgments
The study was funded by the Advanced Project of Beijing Natural Science Foundation (BMU2019GJXK003) and sponsored by Merck Sharp & Dohme Corp (MSD; Beijing, China). The authors had full access to all data in the study and final responsibility for the decision to submit for publication. The authors’ views are independent of the official views of the Beijing Natural Science Committee and MSD.

Authors’ Contributions
At the time of the research, LZ led the development of the questionnaire and interview guidelines. YY, MR, and ZS were responsible for reviewing these documents. ZL and XG were responsible for data collection, and FT, DY, and LN assisted with the field investigation. This manuscript was written by LZ and reviewed by ZS. The two corresponding authors (ZS and XG) contributed equally to this work.

Conflicts of Interest
None declared.

References
1. Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S. Addressing the vaccine confidence gap. The Lancet 2011 Aug 06;378(9790):526-535. [doi: 10.1016/S0140-6736(11)60678-8] [Medline: 21664679]
2. Larson HJ, Smith DMD, Paterson P, Cumming M, Eckerberger E, Freifeld CC, et al. Measuring vaccine confidence: analysis of data obtained by a media surveillance system used to analyse public concerns about vaccines. The Lancet Infectious Diseases 2013 Jul;13(7):606-613. [doi: 10.1016/S1473-3099(13)70108-7] [Medline: 23676442]
3. Coombes R. Europe steps up action against vaccine hesitancy as measles outbreaks continue. BMJ 2017 Oct 16;359:j3151. [doi: 10.1136/bmj.j3151] [Medline: 29038341]
4. MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015 Aug 14;33(34):4161-4164 [FREE Full text] [doi: 10.1016/j.vaccine.2015.04.036] [Medline: 25896383]
5. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heiniinger U, The Brighton Collaboration. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002 Dec 13;21(3-4):298-302. [doi: 10.1016/s0264-410x(02)00449-8] [Medline: 12450705]
6. Edwards KM, Hackell JM, COMMITTEE ON INFECTIOUS DISEASES’ THE COMMITTEE ON PRACTICE AND AMBULATORY MEDICINE. Countering Vaccine Hesitancy. Pediatrics 2016 Sep;138(3):e1-e14 [FREE Full text] [doi: 10.1542/peds.2016-2146] [Medline: 27573085]
7. Crawford NW, Clothier H, Hodgson K, Selvaraj G, Easton ML, Buttery JP. Active surveillance for adverse events following immunization. Expert Rev Vaccines 2014 Feb;13(2):265-276. [doi: 10.1586/14760584.2014.866895] [Medline: 24350637]
8. Baggs J, Gee J, Lewis E, Fowler G, Benson P, Lieu T, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011 May;127(S1):S45-S53. [doi: 10.1542/peds.2010-1722H] [Medline: 21502240]
9. McNeil MM, Gee J, Wintraub ES, Belongia EA, Lee GM, Glanz JM, et al. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine 2014 Sep 22;32(42):5390-5398 [FREE Full text] [doi: 10.1016/j.vaccine.2014.07.073] [Medline: 25108215]
10. Le Saux N, Barrowman NJ, Moore DL, Whitting S, Scheifele D, Halperin S, Members of Canadian Paediatric Society/Health Canada Immunization Monitoring Program-Active (IMPACT). Decrease in Hospital Admissions for Febrile Seizures and Reports of Hypotonic-Hyporesponsive Episodes Presenting to Hospital Emergency Departments Since Switching to Acellular Pertussis Vaccine in Canada: A Report From IMPACT. Pediatrics 2003 Nov;112(5):e348-e353. [doi: 10.1542/peds.112.5.e348] [Medline: 14595075]
11. Moore DL, Le Saux N, Scheifele D, Halperin SA, Members of the Canadian Paediatric Society/Health Canada Immunization Monitoring Program Active (IMPACT). Lack of Evidence of Encephalopathy Related to Pertussis Vaccine: Active Surveillance by IMPACT, Canada, 1993–2002. Pediatr Infect Dis J 2004 Jun;23(6):568-571. [doi: 10.1097/01.inf.0000130075.56368.02] [Medline: 15194842]
12. Amarasinghe A, Black S, Bonhoeffer J, Carvalho SMD, Dodoo A, Eskola J, et al. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization. Vaccine 2013 Apr 22;31(S2):B108-B114. [doi: 10.1016/j.vaccine.2012.10.119] [Medline: 23598471]
13. Zhang LX, Wang HB, Li QZ, Zhao MH, Zhan QM. Big data and medical research in China. BMJ 2018 Feb 05;360:j360 [FREE Full text] [doi: 10.1136/bmj.j5910] [Medline: 29437562]
14. Yang Y, Zhou XF, Gao SQ, Lin HB, Xie YM, Feng YJ, et al. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China. Drug Saf 2018 Jan;41(1):125-137. [doi: 10.1007/s40264-017-0589-z] [Medline: 28815480]
15. Li HL, Lin HB, Zhao HY, Xu Y, Cheng YC, Shen P, et al. Statins use and risk of new-onset diabetes in hypertensive patients: a population-based retrospective cohort study in Yinzhou district, Ningbo city, People’s Republic of China. Ther Clin Risk Manag 2018 May 3;14:823-832 [FREE Full text] [doi: 10.2147/TCRM.S158850] [Medline: 29765224]
16. Lin HB, Tang X, Shen P, Zhang DD, Wu JG, Zhang JY, et al. Using big data to improve cardiovascular care and outcomes in China: a protocol for the CHinese Electronic health Records Research in Yinzhou (CHERRY) Study. BMJ Open 2018 Feb 12;8(2):1-11 [FREE Full text] [doi: 10.1136/bmjopen-2017-019698] [Medline: 29440217]

17. Willame C, Baril L, van den Bosch J, Ferreira GLC, Williams R, Rosillon D, et al. Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies. Pharmacoepidemiol Drug Saf 2016 Dec;25(12):1397-1406 [FREE Full text] [doi: 10.1002/pds.4081] [Medline: 27601179]

18. Liang XF, Li L, Liu DW, Li KL, Wu WD, Zhu BP, et al. Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in China. N Engl J Med 2011 Feb 17;364(7):638-647. [doi: 10.1056/NEJMoa1008553] [Medline: 21288090]

19. Wu J, Xu FJ, Lu L, Lu M, Miao L, Gao T, et al. Safety and Effectiveness of a 2009 H1N1 Vaccine in Beijing. N Engl J Med 2010 Dec 16;363(25):2416-2423. [doi: 10.1056/NEJMoa1006736] [Medline: 21158658]

20. Nguyen M, Ball R, Midthun K, Lieu TA. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012 Jan;21(S1):291-297. [doi: 10.1002/pds.2323] [Medline: 22262619]

21. Li ZG, Yang Y. Rheumatology in China: challenges and development. Rheumatology (Oxford) 2012 Oct;51(10):1733-1734. [doi: 10.1093/rheumatology/ker166] [Medline: 22772322]

22. Yang C, Fang K, Hu YH. [Research status on the epidemiological characteristics of optic neuritis]. Zhonghua Yan Ke Za Zhi 2015 Dec;51(12):946-949. [Medline: 26888277]

23. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf 2018 Apr;41(4):329-346. [doi: 10.1007/s40264-017-0625-z] [Medline: 29280070]

24. Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. The Lancet 2009 Dec 19;374(9707):2115-2122 PMID: 19880171, PMID: 20362814 [FREE Full text] [doi: 10.1016/S0140-6736(09)61877-8] [Medline: 19880172]

25. Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, Kolczak MS, et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol 2006 Aug;59(8):808-818. [doi: 10.1016/j.jclinepi.2005.11.012] [Medline: 16828674]

26. McClure DL, Glanz JM, Xu S, Hambidge SJ, Mulloloy JP, Baggs J. Comparison of epidemiologic methods for active surveillance of vaccine safety. Vaccine 2008 Jun 19;26(26):3341-3345. [doi: 10.1016/j.vaccine.2008.03.074] [Medline: 18462849]

27. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006 May 30;25(10):1768-1797. [doi: 10.1002/sim.2302] [Medline: 1620518]

28. Yih WK, Lieu TA, Kulldorff M, Martin D, McMahill-Walraven CN, Platt R, et al. Intussusception Risk after Rotavirus Vaccination in U.S. Infants. N Engl J Med 2014 Feb 06;370(6):503-512 PMID: 24422677, PMID: 24785219. [doi: 10.1056/NEJMoa13013164] [Medline: 24422676]

29. Carnahan RM. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research. Pharmacoepidemiol Drug Saf 2012 Jan;21(S1):90-99. [doi: 10.1002/pds.2318] [Medline: 22262597]

30. Weber GM, Mandl KD, Kohane IS. Finding the Missing Link for Big Biomedical Data. JAMA 2014 Jun 25;311(24):2479-2780. [doi: 10.1001/jama.2014.4228] [Medline: 24854141]

Abbreviations

- ADEM: acute disseminated encephalomyelitis.
- AEFI: adverse events following immunization.
- CDC: Centers for Disease Control and Prevention.
- DS: death surveillance.
- EMR: electronic medical record.
- GBS: Guillain-Barre syndrome.
- HPV: human papillomavirus.
- HSP: Henoch-Schonlein purpura.
- ICD-10: 10th revision of the International Statistical Classification of Diseases and Related Health Problems.
- ID: identity card.
- IP: immunization program.
- ITP: primary immune thrombocytopenia.
- JRA: juvenile rheumatoid arthritis.
- MCH: maternal and child health care.
- N/A: not available.
- NHC: Ningbo Health Commission.
ON: optic neuritis.
RA: rheumatoid arthritis.
RHR: residents’ health records.
SCCS: self-controlled case series.
SCRI: self-controlled risk interval.
SLE: systemic lupus erythematosus.
VSD: Vaccine Safety Datalink.
VTE: venous thromboembolism.

Please cite as:
Liu Z, Zhang L, Yang Y, Meng R, Fang T, Dong Y, Li N, Xu G, Zhan S
Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China
J Med Internet Res 2020;22(6):e17446
URL: https://www.jmir.org/2020/6/e17446
doi: 10.2196/17446
PMID: 32234696

©Zhike Liu, Liang Zhang, Yu Yang, Ruogu Meng, Ting Fang, Ying Dong, Ning Li, Guozhang Xu, Siyan Zhan. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 01.06.2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.